VertiGIS Acquires Facility Management Software Partner KMS
VertiGIS, a leading geographic information systems (GIS) solution provider and software developer, announced today the completed acquisition of longstanding development partner KMS Computer GmbH. KMS is an established and trusted computer-aided facility management (CAFM) software specialist based in Dresden, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005039/en/
KMS by VertiGIS is an established and proven provider of computer-aided facility management (CAFM) software based in Dresden, Germany. KMS is known for its GEBman software and has been supporting municipalities, industrial, service and utility companies, among others, with their facility and document management requirements since 1990. The flexible, end-to-end solutions are based on the latest web technologies and are suitable for internal or mobile use. (Graphic: Business Wire)
VertiGIS is backed by global, technology-based investment firm Battery Ventures, who began acquiring GIS and location technology-focused companies under the brand in 2017.
Best known for the GEBman software suite, KMS has helped municipal, industry, service, and utility companies with their facility- and document management needs since 1990. Their flexible, end-to-end solutions – based upon the latest web technologies and suitable for in-house or mobile use – integrate access and analysis of factual data, documents, and spatial information for plants, real estate, and capital goods.
For the past 15 years, KMS has worked with VertiGIS to bring ProOffice – a process-oriented software solution with optional GIS connectivity for infrastructure workflows, and built upon GEBman technology – to German, Austrian, and Swiss customers. The integration of KMS into VertiGIS ensures that the strategic planning and development of ProOffice and GEBman continue to be closely coordinated.
"After 30 years, it was time for me to hand over the company to the next generation,” explains Konrad Schulze, founder and Managing Director of KMS. “Due to the successful partnership and cooperation that has existed between KMS and VertiGIS for many years, I know we can combine the greatest strengths of both organizations and expect our joint customers to benefit from the expanded expertise and industry-leading know-how we have developed over the years.”
“Previous sales partners have now become colleagues, and we are looking forward to working together as one team.”
Schulze’s son, Sebastian, will transition from CTO at KMS to assume the co-role of Managing Director together with VertiGIS veteran Theodor Meusburger. KMS’s solution will become an integral part of the VertiGIS offering for all customers and business segments and will be further supported in sales and software development by VertiGIS’s global business units and teams.
“We are excited to have an even closer working relationship with our friends and partners at KMS,” adds Holger Schade, CEO of VertiGIS EMEA. “This transaction will drive additional innovation as we extend our technological capabilities to a broader group around the globe.”
“Facility management solutions are a key strength of VertiGIS’, and the shared development plans for ProOffice and GEBman fit perfectly into our product strategy moving forward.”
About VertiGIS:
VertiGIS is a leading geographic information systems (GIS) solution provider and software developer. Its focus is the development of software solutions and services that help utilities, land management, public sector, energy, telecommunications, and industry customers connect their business processes and location technology. The VertiGIS product portfolio is used by thousands of customers and millions of end-users around the world and is designed to enhance the capabilities of leading mapping software, most notably Esri’s ArcGIS®. Major product brands include UT for ArcGIS®, the 3A product line, Geocortex®, GEONIS, ConnectMaster™, M4® Solutions, GeoOffice, WebOffice and ProOffice. Further information can be found at www.vertigis.com
About Battery Ventures:
Battery strives to invest in cutting-edge, category-defining businesses in markets including software and services, Web infrastructure, consumer Internet, mobile and industrial technologies. Founded in 1983, the firm backs companies at stages ranging from seed to private equity and invests globally from offices in Boston, the San Francisco Bay Area, London, Israel and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
About KMS:
KMS is an established and proven provider of computer-aided facility management (CAFM) software based in Dresden, Germany. KMS is known for its GEBman software and has been supporting municipalities, industrial, service and utility companies, among others, with their facility and document management requirements since 1990. The flexible, end-to-end solutions are based on the latest web technologies and are suitable for internal or mobile use. Learn more at www.gebman.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005039/en/
Contact information
Sabine Parschau, Communications Manager – VertiGIS EMEA
Website: www.vertigis.com
Email: sabine.parschau@vertigis.com
Phone: +49 89 839315 240
Holger Schade, CEO – VertiGIS EMEA
Website: www.vertigis.com
Email: holger.schade@vertigis.com
Phone: +49 89 45026 0
Sebastian Schulze, Co-Managing Director – KMS by VertiGIS
Website: www.gebman.com
Email: sschulze@kms-computer.de
Phone: +49 351 31 50 30
Theodor Meusburger, Co-Managing Director – KMS by VertiGIS/Managing Director – VertiGIS Austria
Website: www.vertigis.at
Email: theodor.meusburger@vertigis.com
Phone: +43 5 9908 0
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom